Table 1.
Summary of clinical characteristics, antibiotic regimens, and outcome of patients treated with cefiderocol for VIM-type-producing Gram-negative bacteria.
| Patients (n = 34) | |
|---|---|
| Men | 24 (71) |
| Age, years, median (IQR) | 59 (53.7–73.4) |
| Age-adjusted Charlson comorbidity index, median (IQR) | 3.5 (2–5) |
| Comorbidities | |
| Solid organ transplantation | 14 (41) |
| Renal impairment (CrCl < 60 mL/min) | 15 (44) |
| Malignancy | 11 (32) |
| Cardiovascular diseases | 7 (21) |
| Chronic obstructive pulmonary disease | 6 (18) |
| Liver cirrhosis | 2 (6) |
| Hematologic transplantation | 1 (3) |
| Admitted to ICU | 9 (27) |
| Infection type | |
| Respiratory tract | 9 (27) |
| Skin and soft tissue | 9 (27) |
| Urinary tract | 7 (21) |
| Bone | 4 (12) |
| Bloodstream infection | 3 (9) |
| Intra-abdominal infection | 2 (6) |
| Positive blood cultures | 8 (24) |
| Drainable source | 17 (50) |
| Drainage performed | 9 (27) |
| Days of treatment with cefiderocol, median (IQR) | 13 (8–24) |
| Patients treated with combination therapy | 9 (27) |
| Nebulized antibiotics | 7 (21) |
| Intravenous antibiotics | 2 (6) |
| Clinical failure at 14 days of follow-up | 5 (15) |
| Death | 3 (9) |
| Persistent infection | 2 (6) |
| All-cause mortality at 30 days of follow-up | 9 (27) |
| Microbiological recurrence at 90 days of follow-up among 25 survivors | 5 (25) |
Data are expressed as the number and percentage unless otherwise indicated.